Predicted to enable PDZ domain binding activity and phosphatidylinositol-3,4-bisphosphate binding activity. Predicted to be involved in several processes, including B cell receptor signaling pathway; negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; and phosphatidylinositol 3-kinase/protein kinase B signal transduction. Predicted to act upstream of or within several processes, including androgen metabolic process; face morphogenesis; and gonad development. Predicted to be located in cytosol; nucleoplasm; and ruffle membrane. Predicted to be active in cytoplasm and membrane. Orthologous to human PLEKHA1 (pleckstrin homology domain containing A1); PARTICIPATES IN phosphatidylinositol 3-kinase class I signaling pathway; INTERACTS WITH (+)-schisandrin B; 2,3,7,8-tetrachlorodibenzodioxine; 4,4'-sulfonyldiphenol.
LOC361659; MGC156706; pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 1; pleckstrin homology domain-containing family A member 1; pleckstrin homology domain-containing protein family A member 1; RGD1564153; similar to Pleckstrin homology domain-containing protein family A member 1 (Tandem PH domain containing protein-1); similar to Pleckstrin homology domain-containing protein family A member 1 (Tandem PH domain containing protein-1) (TAPP-1); tandem PH domain containing protein-1
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of PLEKHA1 mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of PLEKHA1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of PLEKHA1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of PLEKHA1 mRNA
[Clofibrate co-treated with Acetaminophen] affects the expression of PLEKHA1 mRNA and PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of PLEKHA1 mRNA]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of PLEKHA1 mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of PLEKHA1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of PLEKHA1 mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of PLEKHA1 mRNA
[Clofibrate co-treated with Acetaminophen] affects the expression of PLEKHA1 mRNA and PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of PLEKHA1 mRNA]
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHA1 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLEKHA1 mRNA